Navana Pharmaceuticals Statistics

Total Valuation

Navana Pharmaceuticals has a market cap or net worth of BDT 5.38 billion. The enterprise value is 10.63 billion.

Market Cap	5.38B
Enterprise Value	10.63B

Important Dates

The next estimated earnings date is Thursday, January 23, 2025.

Earnings Date	Jan 23, 2025
Ex-Dividend Date	Nov 20, 2024

Share Statistics

Navana Pharmaceuticals has 107.42 million shares outstanding. The number of shares has increased by 1.72% in one year.

Current Share Class	n/a
Shares Outstanding	107.42M
Shares Change (YoY)	+1.72%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	35.49%
Owned by Institutions (%)	n/a
Float	69.30M

Valuation Ratios

The trailing PE ratio is 12.84.

PE Ratio	12.84
Forward PE	n/a
PS Ratio	0.73
PB Ratio	1.15
P/TBV Ratio	1.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.85, with an EV/FCF ratio of -17.66.

EV / Earnings	25.29
EV / Sales	1.44
EV / EBITDA	7.85
EV / EBIT	9.36
EV / FCF	-17.66

Financial Position

The company has a current ratio of 0.91, with a Debt / Equity ratio of 1.19.

Current Ratio	0.91
Quick Ratio	0.22
Debt / Equity	1.19
Debt / EBITDA	4.11
Debt / FCF	-9.25
Interest Coverage	1.95

Financial Efficiency

Return on equity (ROE) is 9.30% and return on invested capital (ROIC) is 7.43%.

Return on Equity (ROE)	9.30%
Return on Assets (ROA)	6.69%
Return on Capital (ROIC)	7.43%
Revenue Per Employee	1.68M
Profits Per Employee	95,332
Employee Count	4,408
Asset Turnover	0.70
Inventory Turnover	1.96

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.99% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-40.99%
50-Day Moving Average	48.83
200-Day Moving Average	75.65
Relative Strength Index (RSI)	48.37
Average Volume (20 Days)	456,635

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Navana Pharmaceuticals had revenue of BDT 7.40 billion and earned 420.22 million in profits. Earnings per share was 3.90.

Revenue	7.40B
Gross Profit	3.37B
Operating Income	1.14B
Pretax Income	527.42M
Net Income	420.22M
EBITDA	1.31B
EBIT	1.14B
Earnings Per Share (EPS)	3.90

Full Income Statement

Balance Sheet

The company has 270.83 million in cash and 5.57 billion in debt, giving a net cash position of -5.25 billion or -48.86 per share.

Cash & Cash Equivalents	270.83M
Total Debt	5.57B
Net Cash	-5.25B
Net Cash Per Share	-48.86
Equity (Book Value)	4.67B
Book Value Per Share	43.51
Working Capital	-588.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 794.56 million and capital expenditures -1.40 billion, giving a free cash flow of -601.78 million.

Operating Cash Flow	794.56M
Capital Expenditures	-1.40B
Free Cash Flow	-601.78M
FCF Per Share	-5.60

Full Cash Flow Statement

Margins

Gross margin is 45.54%, with operating and profit margins of 15.34% and 5.75%.

Gross Margin	45.54%
Operating Margin	15.34%
Pretax Margin	7.12%
Profit Margin	5.75%
EBITDA Margin	17.73%
EBIT Margin	15.34%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 2.79%.

Dividend Per Share	1.40
Dividend Yield	2.79%
Dividend Growth (YoY)	7.69%
Years of Dividend Growth	2
Payout Ratio	32.14%
Buyback Yield	-1.72%
Shareholder Yield	1.08%
Earnings Yield	7.79%
FCF Yield	-11.18%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Navana Pharmaceuticals has an Altman Z-Score of 1.83. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.83
Piotroski F-Score	n/a